What is the current stock price of Cipher Pharmaceuticals Inc. (CPHRF)?

As of the latest market data, Cipher Pharmaceuticals Inc. (CPHRF) is trading at $11.87. The stock has seen a loss of -3.54% today.

Does Cipher Pharmaceuticals Inc. (CPHRF) pay a dividend?

Based on current data, Cipher Pharmaceuticals Inc. does not have a confirmed active dividend policy.

What is the market cap of Cipher Pharmaceuticals Inc.?

The current market capitalization of Cipher Pharmaceuticals Inc. (CPHRF) is approximately unavailable.

CPHRF

Cipher Pharmaceuticals Inc.·Healthcare

11.87

3.535%(−0.43)

Close Price

12.08

1.769%(+0.21)

After Hours

Last Updated: — ET

52W L: $8.6452W H: $15.00

CPHRF NEWS

seekingalpha.com

May 8

Cipher Pharmaceuticals Inc. (CPH:CA) Q1 2026 Earnings Call Transcript

businesswire.com

Apr 7

CaryHealth Launches Direct-to-Patient Program for Cipher Pharmaceuticals' Natroba™ (spinosad)

WASHINGTON--(BUSINESS WIRE)-- #DTP--CaryHealth, a leading digital health company, today announced the launch of its direct-to-patient (DTP) platform to support seamless access to Natroba (spinosad), a prescription treatment for head lice and scabies, in partnership with Cipher Pharmaceuticals US LLC (Cipher or Cipher Pharmaceuticals). Through this partnership, CaryHealth has designed an online custom platform to both access and quickly deliver Natroba (spinosad) to patients, which eliminates common ob.

defenseworld.net

Mar 31

Cipher Pharmaceuticals (OTCMKTS:CPHRF) Stock Price Crosses Above 50 Day Moving Average – Should You Sell?

Cipher Pharmaceuticals Inc. (OTCMKTS:CPHRF - Get Free Report) (TSE: CPH)'s share price passed above its fifty day moving average during trading on Monday. The stock has a fifty day moving average of $11.18 and traded as high as $13.28. Cipher Pharmaceuticals shares last traded at $13.00, with a volume of 8,501 shares traded. Cipher Pharmaceuticals

seekingalpha.com

Mar 13

Cipher Pharmaceuticals Inc. (CPH:CA) Q4 2025 Earnings Call Transcript

Company Profile

Cipher Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada. Its commercial products include Epuris (CIP-ISOTRETINOIN), a formulation of the active ingredient isotretinoin for use in the treatment of severe acne; Ozenoxacin to treat adult and paediatric patients with impetigo; Actikerall, which is indicated for the treatment of palpable or moderately thick hyperkeratotic actinic keratosis; Vaniqa, a prescription cream that reduces the growth of unwanted facial hair in women; BRINAVESS, a treatment for sinus rhythm in adults; and AGGRASTAT, an intravenous anti-platelet drug. The company's licensed products comprise CIP-Isotretinoin; Lipofen (CIP-Fenofibrate), a formulation of the active ingredient fenofibrate used for the treatment of hyperlipidemia, a cholesterol disorder; and Conzip/Durela (CIP- Tramadol), a formulation of the active ingredient tramadol for the management of moderate to moderately severe pain. Its pipeline products include Trevyent, a vasodilatory prostacyclin analogue to treat pulmonary arterial hypertension; CF-101 for severe plaque psoriasis and rheumatoid arthritis; MOB-015, a topical formulation of terbinafine for the treatment of onychomycosis; and DTR-001, a tattoo removal cream. Cipher Pharmaceuticals Inc. was founded in 2000 and is headquartered in Oakville, Canada.

Sector

Healthcare

Industry

Drug Manufacturers - Specialty & Generic

Employees

IPO Date

2006-02-02

Beta

-0.16

Websitewww.cipherpharma.com↗